Investment Research & Advisory Group Inc. Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Investment Research & Advisory Group Inc. increased its stake in Eli Lilly and Company by 6.1%, now holding 7,108 shares worth approximately $5.54 million.
• Several other investors, including WestEnd Advisors LLC and Citizens National Bank Trust Department, significantly increased their positions in Eli Lilly during the first quarter.
• Despite recent price target reductions from analysts, Eli Lilly reported strong earnings of $6.31 per share, exceeding estimates, with a revenue increase of 37.6% year-over-year.

Investment Research & Advisory Group Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,108 shares of the company's stock after buying an additional 411 shares during the quarter. Eli Lilly and Company comprises about 2.1% of Investment Research & Advisory Group Inc.'s holdings, making the stock its 12th biggest holding. Investment Research & Advisory Group Inc.'s holdings in Eli Lilly and Company were worth $5,541,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. WestEnd Advisors LLC grew its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at $40,000. Finally, TD Capital Management LLC increased its stake in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Cantor Fitzgerald cut their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Leerink Partners reissued a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $724.73 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The company has a 50-day simple moving average of $734.15 and a 200-day simple moving average of $766.60. The company has a market capitalization of $685.93 billion, a PE ratio of 47.37, a P/E/G ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.